With demand for antiviral drugs skyrocketing amid the COVID-19 outbreak in China, the CCP says it will remove a certain medication from its health insurance drug list in April.
The targeted drug is called Paxlovid— an antiviral made by U.S. drug maker Pfizer.
Chinese authorities attributed the removal to a high price for the COVID-19 drug quoted by the U-S firm.